Justin Mortara, CEO
EnsoData is a commercial-stage clinical AI company offering a SaaS platform that enables providers to diagnose, treat, and monitor patients more efficiently.

Their story
An estimated 50-70 million Americans suffer from chronic sleep disorders, 80% of whom remain undiagnosed and untreated. Despite growing awareness of this unmet need among both providers and patients, traditional approaches to diagnosing and treating sleep disorders have struggled to scale. Today, this supply-demand mismatch is reducing patient access and straining health systems.
Founded in 2014, EnsoData set out to apply AI to waveform data – continuous signals like heartbeats or brain waves from medical devices – to help providers more effectively spot patterns, diagnose conditions, and monitor patients. Recognizing a major need in sleep medicine, EnsoData launched its first FDA-cleared AI tools to automate and accelerate complex in-lab sleep study scoring. From this foundation, the company has grown into a broad sleep health platform, offering proprietary software for at-home diagnostics, sleep therapy management, and remote patient monitoring.


.avif)


Our partnership
We were fortunate enough to have known and built a relationship with EnsoData over several years before making an investment. Over that period, we were consistently impressed with the company’s pace of clinical innovation and product commercialization. When the company set out to raise a Series B, it stood out among the cohort of Clinical AI companies we had been tracking as part of a multi-year thesis.
We’re thrilled to partner with an experienced management team at the helm of an innovative technology. EnsoData is well on its way to becoming a category leader in sleep, and we’re excited for the expansion opportunities that the company’s flexible technology lends itself to and beyond.